While not typically found in healthy brain cells, non-mutated EGFR is frequently expressed by glioblastoma cells. The INCIPIENT trial was a phase 1 study designed to test the safety and potential ...

Although in the past 5 years, there have been a large number of phase II clinical trials with single-targeted agents, such as EGFR inhibitors in patients with malignant gliomas, most of these ...

Black Diamond Therapeutics presents a compelling investment opportunity with strong potential, balanced by inherent biotech ...

An EGFR gene mutation is one of the biomarkers a doctor often tests for after confirming a diagnosis of non-small cell lung cancer (NSCLC). Biomarkers can help guide treatment. EGFR mutations ...

They then focused on glioblastoma multiforme (GBM ... differences in immune system activity and genetic mutations—such as EGFR alterations—were linked to worse survival in LGG patients ...

Clinical studies of proton therapy have been performed for several types of tumors, including gliomas. [64] Fitzek et al. conducted a Phase II study of 23 GBM patients treated with radiation dose ...

The glioma tumors from 17 individuals (with an average fire-fighting history of 22 years) were compared with those from 18 individuals in non-firefighting occupations.

“We also look forward to the expansion in the first quarter of 2025 of the investigator sponsored window of opportunity trial of BDTX-1535 into newly diagnosed glioblastoma patients with EGFR ...

“We also look forward to the expansion in the first quarter of 2025 of the investigator sponsored window of opportunity trial of BDTX-1535 into newly diagnosed glioblastoma patients with EGFR ...